Pulmatrix, Inc.
No enriched coverage for $PULM in the last 7 days.
No SEC Form 4 filings for $PULM in the last 30 days.
See all $PULM insider activity →Pulmatrix (Nasdaq: PULM) reported 2Q 2026 results and updated investors on its proposed merger with privately held Eos SENOLYTIX. Pulmatrix filed an S-4 and said the deal is expected to close in 3Q 2026. It raised $1.0 million via a private placement. Cash was $2.2 million at June 30, 2026.
Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX Framingham, Mass., August 13, 2026 – Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharm
Monteverde & Associates PC says it is investigating merger-related claims involving Pulmatrix (PULM) and Eos SenolyTix, Simulations Plus (SLP) and Altaris affiliates, Olin (OLN) and Huntsman (HUN). It cites expected ownership and deal terms, including $18.50 per SLP share cash and Huntsman receiving 0.5476 OLN shares. Shareholder votes are scheduled for Aug. 25, 2026.
Recent PULM coverage spans mergers & acquisitions, financial news and earnings.
Near-term trading focus is merger execution risk plus cash runway, with additional read-through from Q2 cost and liquidity disclosures.
Near-term trading focus is merger execution risk plus cash runway, while clinical programs are paused pending monetization/licensing.
A shareholder class-action legal inquiry is being launched around the proposed merger terms and expected ownership split.
The announced merger between Pulmatrix and Eos SENOLYTIX is a significant development in the biotech sector, particularly in anti-aging therapeutics. The deal could positively influence PULM's stock, reflecting investor optimism about the company's growth prospects in this niche.
Pulmatrix (PULM) reported a 100% revenue decline in Q2 2025, indicating severe operational challenges or strategic setbacks.
alphai scores every news story that mentions PULM with an AI model for sentiment and relevance, and aggregates insider trades from Pulmatrix, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pulmatrix (Nasdaq: PULM) reported 2Q 2026 results and updated investors on its proposed merger with privately held Eos SENOLYTIX. Pulmatrix filed an S-4 and said the deal is expected to close in 3Q 2026. It raised $1.0 million via a private placement. Cash was $2.2 million at June 30, 2026.
6 min readPulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX Framingham, Mass., August 13, 2026 – Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharm
5 min readMonteverde & Associates PC says it is investigating merger-related claims involving Pulmatrix (PULM) and Eos SenolyTix, Simulations Plus (SLP) and Altaris affiliates, Olin (OLN) and Huntsman (HUN). It cites expected ownership and deal terms, including $18.50 per SLP share cash and Huntsman receiving 0.5476 OLN shares. Shareholder votes are scheduled for Aug. 25, 2026.
2 min readPulmatrix, Inc. has announced a definitive merger agreement to acquire Eos SENOLYTIX, Inc. in a $19 million deal. The combined entity will operate as Eos SENOLYTIX, Inc., trading on Nasdaq under "EOSX," and will focus on developing peptide therapies for aging-related diseases, particularly sarcopenia, through Eos’s MitoXcel platform. The transaction, which includes concurrent private financings, is subject to stockholder approval and regulatory requirements and is expected to close in mid-2026.
4 min readPulmatrix ( NASDAQ:PULM ) , a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that ended June 30, 2025. Pulmatrix reported zero revenue for the period ended June 30, 2025.
2 min read
